US 12,257,246 B2
Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide
Alison Pilgrim, La Jolla, CA (US); James F. White, Carlisle, MA (US); and Nadia M. J. Rupniak, Cary, NC (US)
Assigned to COLUCID PHARMACEUTICALS, INC., Indianapolis, IN (US)
Filed by CoLucid Pharmaceuticals, Inc., Indianapolis, IN (US)
Filed on Sep. 14, 2021, as Appl. No. 17/474,203.
Application 17/474,203 is a continuation of application No. 12/753,489, filed on Apr. 2, 2010, abandoned.
Claims priority of provisional application 61/166,097, filed on Apr. 2, 2009.
Prior Publication US 2021/0401822 A1, Dec. 30, 2021
Int. Cl. A61K 31/4545 (2006.01)
CPC A61K 31/4545 (2013.01) 5 Claims
 
1. A method for the acute treatment of migraine in a human subject in need thereof consisting of oral administration to said subject a pharmaceutical composition adapted for oral delivery, the composition comprising 50 to 200 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier, wherein said composition is administered up to 200 mg daily.